139 related articles for article (PubMed ID: 21278444)
1. Coming of age: breast cancer in seniors.
Muss HB
Oncologist; 2011; 16 Suppl 1():79-87. PubMed ID: 21278444
[TBL] [Abstract][Full Text] [Related]
2. Coming of age: breast cancer in seniors.
Muss HB
Oncologist; 2010; 15 Suppl 5():57-65. PubMed ID: 21138956
[TBL] [Abstract][Full Text] [Related]
3. Directed therapy of subtypes of triple-negative breast cancer.
Carey LA
Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
[TBL] [Abstract][Full Text] [Related]
4. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy.
Montemurro F; Aglietta M
Endocr Relat Cancer; 2009 Dec; 16(4):1091-102. PubMed ID: 19726539
[TBL] [Abstract][Full Text] [Related]
5. Molecular stratification of triple-negative breast cancers.
Perou CM
Oncologist; 2011; 16 Suppl 1():61-70. PubMed ID: 21278442
[TBL] [Abstract][Full Text] [Related]
6. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
7. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
8. [Effective treatment strategy in elderly breast cancer patients].
Boér K
Orv Hetil; 2005 Jan; 146(1):15-21. PubMed ID: 15715368
[TBL] [Abstract][Full Text] [Related]
9. [Triple-negative breast carcinoma--rewiev of current literature].
Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
[TBL] [Abstract][Full Text] [Related]
10. Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective?
Naeim A; Keeler EB
Crit Rev Oncol Hematol; 2005 Jan; 53(1):81-9. PubMed ID: 15607936
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
12. Molecular predictors of response to therapy for breast cancer.
Galanina N; Bossuyt V; Harris LN
Cancer J; 2011; 17(2):96-103. PubMed ID: 21427553
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy is not for everyone.
Henderson IC
Breast Cancer Res Treat; 2010 Aug; 123(1):159-62. PubMed ID: 20549338
[No Abstract] [Full Text] [Related]
15. Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?
Biganzoli L; Claudino WM; Pestrin M; Pozzessere D; Di Leo A
Crit Rev Oncol Hematol; 2007 Apr; 62(1):1-8. PubMed ID: 17317203
[TBL] [Abstract][Full Text] [Related]
16. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?
Park YH; Kim ST; Cho EY; Choi YL; Ok ON; Baek HJ; Lee JE; Nam SJ; Yang JH; Park W; Choi DH; Huh SJ; Ahn JS; Im YH
Breast Cancer Res Treat; 2010 Feb; 119(3):653-61. PubMed ID: 19957028
[TBL] [Abstract][Full Text] [Related]
17. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients.
DeMichele A; Putt M; Zhang Y; Glick JH; Norman S
Cancer; 2003 May; 97(9):2150-9. PubMed ID: 12712466
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer in the elderly.
Crivellari D; Aapro M; Leonard R; von Minckwitz G; Brain E; Goldhirsch A; Veronesi A; Muss H
J Clin Oncol; 2007 May; 25(14):1882-90. PubMed ID: 17488987
[TBL] [Abstract][Full Text] [Related]
19. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
20. Relation between pathomorphological response in tumors after neoadjuvant chemotherapy and clinico-morphological and molecular prognostic factors in patients with breast cancer.
Timovska YO; Pivnyuk VM; Oliynichenko GP; Anikushko MF; Zachartseva LM; Chekhun VF
Exp Oncol; 2009 Dec; 31(4):231-6. PubMed ID: 20010529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
